Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07032610 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-term Immunogenicity of L-HAV Vaccine Among Healthy Thai Children and Adolescents

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Active, Not Recruitingv2 Show 4 more changesShow less
    • Primary completion date changed from estimate of Aug 31, 2025 to Jun 28, 2025
    • Study completion date: Sep 30, 2025 to Jul 31, 2026
    • Start date changed from estimate of Jun 22, 2025 to Jun 26, 2025
    • Site contact updated
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Hepatitis A virus (HAV) remains a common infection among Thai children. Two types of HAV vaccines are available in Thailand: an inactivated vaccine (I-HAV, administered in two doses 6 months apart) and a live-attenuated vaccine (L-HAV, administered as a single dose). However, neither vaccine is currently included in Thailand's Expanded Programme on Immunization (EPI). In 2024, a randomized, active-controlled, open-label, non-inferiority trial was conducted to compare the immunogenicity and safety of the two-dose I-HAV with the single-dose L-HAV in healthy Thai children and adolescents aged 18 months to 18 years. This study aims to evaluate the long-term seropositive rate and immunogenicity of anti-HAV antibodies in this population following a single dose of L-HAV.
Trial Details
NCT Number NCT07032610
Lead Sponsor Chiang Mai University
Collaborators: Faculty of Medicine, Chiang Mai University
Conditions
(from sponsor)		 Hepatitis A, Hepatitis A Virus, Vaccine-Preventable Diseases
Related terms Hepatitis, Hepatitis A, Vaccine-Preventable Diseases
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov